Form 4: Zimmer Biomet Director Acquires Additional Phantom Stock Units

Syed A. Jafry, a Director at Zimmer Biomet Holdings, Inc., acquired 178.355 phantom stock units on June 30, 2025, increasing his beneficial ownership to 7,153.79 units as part of a deferred compensation plan.

Summary

• Syed A. Jafry, a Director of Zimmer Biomet Holdings, Inc. (ZBH), acquired 178.355 phantom stock units.
• The transaction occurred on June 30, 2025.
• These units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• Each phantom stock unit is convertible into one share of Zimmer Biomet common stock.
• Following this acquisition, Syed A. Jafry beneficially owns a total of 7,153.79 phantom stock units.
• The units are to be settled in shares of company common stock within sixty days after the reporting person ceases service as a Director.

Sentiment

Score: 7

Explanation: The acquisition of phantom stock units by a director is a positive signal of continued alignment with shareholder interests and participation in a standard compensation plan. It's a routine, expected event, not indicative of major positive or negative news, hence a neutral-to-slightly positive score.

Positives

• Acquisition of phantom stock units by a director indicates continued alignment of interests with shareholders.
• Participation in the Deferred Compensation Plan for Non-Employee Directors suggests a structured approach to executive compensation and retention.

Negatives

• No specific negatives are apparent from this Form 4 filing, as it primarily reports a routine compensation-related transaction.

Risks

• No specific risks are mentioned in this Form 4 filing, which is a transaction report, not a comprehensive risk disclosure.

Future Outlook

The phantom stock units are scheduled to be settled in shares of Zimmer Biomet Holdings, Inc. common stock within sixty days after Syed A. Jafry ceases his service as a Director.

Industry Context

This transaction is a routine insider filing common in the medical device and healthcare industry, reflecting standard non-employee director compensation practices. It does not provide broader industry trends but indicates ongoing equity-based compensation for board members, a common practice to align director interests with long-term company performance.

Comparison to Industry Standards

• The use of phantom stock units as part of non-employee director compensation is a common practice across various industries, including medical devices, aligning director incentives with shareholder value without immediate share issuance.
• The 1-for-1 conversion ratio to common stock is standard for such equity-linked compensation vehicles.
• Companies like Stryker Corporation (SYK) and Johnson & Johnson (JNJ), also prominent in the medical device sector, similarly utilize equity-based compensation plans for their non-employee directors to foster long-term commitment and performance alignment.

Stakeholder Impact

• Shareholders: The transaction aligns the director's interests with shareholders through equity-based compensation, potentially fostering long-term value creation.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• Settlement of the phantom stock units into shares of Zimmer Biomet common stock within sixty days after Syed A. Jafry's cessation of service as a Director.

Key Dates

Recommendation

Keywords

Zimmer Biomet Holdings, ZBH, Syed A. Jafry, Form 4, SEC filing, insider transaction, phantom stock units, deferred compensation, director compensation, equity acquisition